Literature DB >> 29850837

Neurosurgeons still wanted.

Daniel W Fults1.   

Abstract

Mesh：

Year:  2018        PMID： 29850837      PMCID： PMC6071658          DOI： 10.1093/neuonc/noy081

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  7 in total

1.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Authors:  M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

2.  Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Authors:  Benjamin M Ellingson; Lauren E Abrey; Sarah J Nelson; Timothy J Kaufmann; Josep Garcia; Olivier Chinot; Frank Saran; Ryo Nishikawa; Roger Henriksson; Warren P Mason; Wolfgang Wick; Nicholas Butowski; Keith L Ligon; Elizabeth R Gerstner; Howard Colman; John de Groot; Susan Chang; Ingo Mellinghoff; Robert J Young; Brian M Alexander; Rivka Colen; Jennie W Taylor; Isabel Arrillaga-Romany; Arnav Mehta; Raymond Y Huang; Whitney B Pope; David Reardon; Tracy Batchelor; Michael Prados; Evanthia Galanis; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

3.  Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.

Authors:  Kaisorn L Chaichana; Ignacio Jusue-Torres; Rodrigo Navarro-Ramirez; Shaan M Raza; Maria Pascual-Gallego; Aly Ibrahim; Marta Hernandez-Hermann; Luis Gomez; Xiaobu Ye; Jon D Weingart; Alessandro Olivi; Jaishri Blakeley; Gary L Gallia; Michael Lim; Henry Brem; Alfredo Quinones-Hinojosa
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

4.  Surgical treatment of glioblastoma in the elderly: the impact of complications.

Authors:  Michael Karsy; Nam Yoon; Lillian Boettcher; Randy Jensen; Lubdha Shah; Joel MacDonald; Sarah T Menacho
Journal:  J Neurooncol       Date:  2018-02-01       Impact factor: 4.130

5.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

Review 7.  Glioma extent of resection and its impact on patient outcome.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Neurosurgery       Date:  2008-04       Impact factor: 4.654
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.